Risk and the efficacy of antiinflammatory agents: Retrospective and confirmatory studies of sepsis

Peter Q. Eichacker, Chantal Parent, Andre Kalil, Claire Esposito, Xizhong Cui, Steven M. Banks, Eric P. Gerstenberger, Yvonne Fitz, Robert L. Danner, Charles Natanson

Research output: Contribution to journalArticle

281 Citations (Scopus)

Abstract

We investigated whether a relationship between risk of death and treatment effect could explain the disparate results between the preclinical and clinical sepsis trials of antiinflammatory agents over the last decade. A metaregression analysis of cited preclinical studies showed that the treatment effects of these agents were highly dependent on risk of death (p = 0.0001) and that animals were studied at significantly higher control mortality rates than humans (median [25th-75th quartile], 88% [79-96%] versus 39% [32-42%], p = 0.0001). An analysis of the clinical trials showed that antiinflammatory agents were also significantly more efficacious in septic patients with higher risk of death (p = 0.002) and were harmful in those with low risk. To test this relationship prospectively, we studied antiinflammatory agents in models employing differing doses of bacterial challenge to produce the full range of risk of death. We found that the efficacy of these agents, although very beneficial at high control mortality rates, was much reduced (p = 0.0001) and similar to those in human trials at moderate control mortality rates (i.e., 30 to 40%). The efficacy of antiinflammatory agents during sepsis is dependent on the risk of death, an observation that explains the apparent contradiction between preclinical and clinical trial results. Accounting for this relationship may be necessary for the safe and effective development of antiinflammatory therapies for sepsis.

Original languageEnglish (US)
Pages (from-to)1197-1205
Number of pages9
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume166
Issue number9
DOIs
StatePublished - Nov 1 2002

Fingerprint

Sepsis
Anti-Inflammatory Agents
Retrospective Studies
Clinical Trials
Mortality
Therapeutics
Observation

Keywords

  • Antiinflammatory therapies
  • Metaregression analysis
  • Preclinical and clinical trials
  • Septic shock

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Risk and the efficacy of antiinflammatory agents : Retrospective and confirmatory studies of sepsis. / Eichacker, Peter Q.; Parent, Chantal; Kalil, Andre; Esposito, Claire; Cui, Xizhong; Banks, Steven M.; Gerstenberger, Eric P.; Fitz, Yvonne; Danner, Robert L.; Natanson, Charles.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 166, No. 9, 01.11.2002, p. 1197-1205.

Research output: Contribution to journalArticle

Eichacker, PQ, Parent, C, Kalil, A, Esposito, C, Cui, X, Banks, SM, Gerstenberger, EP, Fitz, Y, Danner, RL & Natanson, C 2002, 'Risk and the efficacy of antiinflammatory agents: Retrospective and confirmatory studies of sepsis', American Journal of Respiratory and Critical Care Medicine, vol. 166, no. 9, pp. 1197-1205. https://doi.org/10.1164/rccm.200204-302OC
Eichacker, Peter Q. ; Parent, Chantal ; Kalil, Andre ; Esposito, Claire ; Cui, Xizhong ; Banks, Steven M. ; Gerstenberger, Eric P. ; Fitz, Yvonne ; Danner, Robert L. ; Natanson, Charles. / Risk and the efficacy of antiinflammatory agents : Retrospective and confirmatory studies of sepsis. In: American Journal of Respiratory and Critical Care Medicine. 2002 ; Vol. 166, No. 9. pp. 1197-1205.
@article{c8ca5184d9944a4a869addfd9b170b9a,
title = "Risk and the efficacy of antiinflammatory agents: Retrospective and confirmatory studies of sepsis",
abstract = "We investigated whether a relationship between risk of death and treatment effect could explain the disparate results between the preclinical and clinical sepsis trials of antiinflammatory agents over the last decade. A metaregression analysis of cited preclinical studies showed that the treatment effects of these agents were highly dependent on risk of death (p = 0.0001) and that animals were studied at significantly higher control mortality rates than humans (median [25th-75th quartile], 88{\%} [79-96{\%}] versus 39{\%} [32-42{\%}], p = 0.0001). An analysis of the clinical trials showed that antiinflammatory agents were also significantly more efficacious in septic patients with higher risk of death (p = 0.002) and were harmful in those with low risk. To test this relationship prospectively, we studied antiinflammatory agents in models employing differing doses of bacterial challenge to produce the full range of risk of death. We found that the efficacy of these agents, although very beneficial at high control mortality rates, was much reduced (p = 0.0001) and similar to those in human trials at moderate control mortality rates (i.e., 30 to 40{\%}). The efficacy of antiinflammatory agents during sepsis is dependent on the risk of death, an observation that explains the apparent contradiction between preclinical and clinical trial results. Accounting for this relationship may be necessary for the safe and effective development of antiinflammatory therapies for sepsis.",
keywords = "Antiinflammatory therapies, Metaregression analysis, Preclinical and clinical trials, Septic shock",
author = "Eichacker, {Peter Q.} and Chantal Parent and Andre Kalil and Claire Esposito and Xizhong Cui and Banks, {Steven M.} and Gerstenberger, {Eric P.} and Yvonne Fitz and Danner, {Robert L.} and Charles Natanson",
year = "2002",
month = "11",
day = "1",
doi = "10.1164/rccm.200204-302OC",
language = "English (US)",
volume = "166",
pages = "1197--1205",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "9",

}

TY - JOUR

T1 - Risk and the efficacy of antiinflammatory agents

T2 - Retrospective and confirmatory studies of sepsis

AU - Eichacker, Peter Q.

AU - Parent, Chantal

AU - Kalil, Andre

AU - Esposito, Claire

AU - Cui, Xizhong

AU - Banks, Steven M.

AU - Gerstenberger, Eric P.

AU - Fitz, Yvonne

AU - Danner, Robert L.

AU - Natanson, Charles

PY - 2002/11/1

Y1 - 2002/11/1

N2 - We investigated whether a relationship between risk of death and treatment effect could explain the disparate results between the preclinical and clinical sepsis trials of antiinflammatory agents over the last decade. A metaregression analysis of cited preclinical studies showed that the treatment effects of these agents were highly dependent on risk of death (p = 0.0001) and that animals were studied at significantly higher control mortality rates than humans (median [25th-75th quartile], 88% [79-96%] versus 39% [32-42%], p = 0.0001). An analysis of the clinical trials showed that antiinflammatory agents were also significantly more efficacious in septic patients with higher risk of death (p = 0.002) and were harmful in those with low risk. To test this relationship prospectively, we studied antiinflammatory agents in models employing differing doses of bacterial challenge to produce the full range of risk of death. We found that the efficacy of these agents, although very beneficial at high control mortality rates, was much reduced (p = 0.0001) and similar to those in human trials at moderate control mortality rates (i.e., 30 to 40%). The efficacy of antiinflammatory agents during sepsis is dependent on the risk of death, an observation that explains the apparent contradiction between preclinical and clinical trial results. Accounting for this relationship may be necessary for the safe and effective development of antiinflammatory therapies for sepsis.

AB - We investigated whether a relationship between risk of death and treatment effect could explain the disparate results between the preclinical and clinical sepsis trials of antiinflammatory agents over the last decade. A metaregression analysis of cited preclinical studies showed that the treatment effects of these agents were highly dependent on risk of death (p = 0.0001) and that animals were studied at significantly higher control mortality rates than humans (median [25th-75th quartile], 88% [79-96%] versus 39% [32-42%], p = 0.0001). An analysis of the clinical trials showed that antiinflammatory agents were also significantly more efficacious in septic patients with higher risk of death (p = 0.002) and were harmful in those with low risk. To test this relationship prospectively, we studied antiinflammatory agents in models employing differing doses of bacterial challenge to produce the full range of risk of death. We found that the efficacy of these agents, although very beneficial at high control mortality rates, was much reduced (p = 0.0001) and similar to those in human trials at moderate control mortality rates (i.e., 30 to 40%). The efficacy of antiinflammatory agents during sepsis is dependent on the risk of death, an observation that explains the apparent contradiction between preclinical and clinical trial results. Accounting for this relationship may be necessary for the safe and effective development of antiinflammatory therapies for sepsis.

KW - Antiinflammatory therapies

KW - Metaregression analysis

KW - Preclinical and clinical trials

KW - Septic shock

UR - http://www.scopus.com/inward/record.url?scp=0036840629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036840629&partnerID=8YFLogxK

U2 - 10.1164/rccm.200204-302OC

DO - 10.1164/rccm.200204-302OC

M3 - Article

C2 - 12403688

AN - SCOPUS:0036840629

VL - 166

SP - 1197

EP - 1205

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 9

ER -